As a combined entity, Virgin Pulse and HealthComp will serve more than 1,000 self-insured employers and more than 20 million members. New Mountain Capital will be the majority owner.
The era of remote patient monitoring is ushering in a new era of healthcare, characterized by data-driven insights, personalized care, and efficient resource utilization. Learn More>>
If you haven't already - You still have time to provide us feedback on what works for you and what doesn't on MedCity News. Please take a few moments to share your thoughts. At the end of the survey, you can enter to win a $250 gift card. Thank you.
NurOwn, Brainstorm Cell Therapeutics' experimental stem cell therapy for ALS, did not win the backing of an independent panel of FDA advisors. Many advisory committee members said they want to see more data from another clinical trial, the same guidance the FDA has given the biotech for nearly three years.
Evvy's $14 million funding round was led by Left Lane Capital and included participation from General Catalyst, LabCorp Venture Fund, RH Capital, Ingeborg Investments, G9 Ventures, Virtue and Amboy Street Ventures. In total, Evvy has raised $19 million.
Transcarent announced a new provider network, which seeks to help its employer customers provide their staff with access to high-quality, affordable care. The network includes 10 health systems — including Mount Sinai, Mass General Brigham and Intermountain Health.
In the inaugural episode of the MedCity FemFwd podcast, Michelle Long, senior policy analyst for the Women's Health Policy program at KFF, talks about Opill, which recently made headlines as the first daily oral contraceptive approved for nonprescription use in the U.S. Long tells listeners why this news is significant and examines whether the medication will be covered by insurance.
No comments